<DOC>
	<DOCNO>NCT00420966</DOCNO>
	<brief_summary>The purpose study determine utilization pattern compliance rate palivizumab , monoclonal antibody therapy use prevent respiratory syncytial virus infection .</brief_summary>
	<brief_title>Utilization Compliance Respiratory Syncytial Virus Monoclonal Antibody Therapy</brief_title>
	<detailed_description>Respiratory syncytial virus ( RSV ) important viral respiratory pathogen child . Infection due RSV represent large public health burden ; Canada , account 5,800 hospitalization annually . The peak incidence RSV disease occur 2-6 month age half infant infect first year life . Palivizumab approve prevention serious low respiratory tract disease cause RSV pediatric patient high-risk RSV disease . These child include born premature , bronchopulmonary dysplasia ( BPD ) , hemodynamically significant congenital heart disease ( CHD ) . With recent approval palivizumab Canada , access medication increase . However , limited data utilization , compliance , health outcome , particularly frequency severity RSV infection . The primary objective study provide insight current management ( utilization , compliance ) child high-risk RSV infection palivizumab prophylaxis tertiary care center community setting development Canadian Registry Database .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All child receive least one dose palivizumab The child 's parent legal guardian could communicate either English French The child receive palivizumab part clinical trial study period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>low respiratory tract infection</keyword>
	<keyword>respiratory syncytial virus infection</keyword>
	<keyword>palivizumab</keyword>
	<keyword>outcome</keyword>
	<keyword>utilization</keyword>
	<keyword>compliance</keyword>
</DOC>